Asthma, Allergy, Immunology
Mark Archambault, DHSc, PA-C, DFAAPA
Evaluation and treatment of Asthma have undergone a significant paradigm shift in the past number of years with the introduction of the Global Initiative for Asthma (GINA) strategy report in 2019 that removed the term mild intermittent asthma and eliminated the global use of albuterol/short-acting-beta agonist as a mainstay for acute and abortive therapy.
With 25 million Americans continuing to be affected by this condition, the need for ongoing improvement of prevention when possible and appropriate management when diagnosed is imperative. Identification of various phenotypes to help target specific therapies has significantly reduced hospitalizations and emergency room visits for acute exacerbations.
This review article will review the physiology, revised guidelines for treatment, identify phenotypes and discuss prevention strategies for developing disease and reducing exacerbations.
Baye R. Asthma: Quit Taking My Breath Away. Disease Review and Treatment Summary. Lynchburg Journal of Medical Science. 2023; 5(1).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.